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 Key points: 
 
• Most patients with acute pancreatitis have a self-limiting disease that 
resolves with simple supportive measures. 
 
• Patients with organ dysfunction should be managed in conjunction with 
Critical Care. Those with severe acute pancreatitis should be 
discussed with regional specialist pancreatic units. 
 
• Local complications are managed conservatively as far as possible as 
the risk of intervention is particularly high in the first few weeks. When 
intervention is required, a ‘step-up’ strategy is adopted and an 
endoscopic approach may be preferred. 
 
• Antibiotics are reserved for proven or strongly suspected sepsis. TPN 
is indicated when enteral nutrition fails or is contraindicated. 
 
• Aetiology should be addressed to prevent recurrence. 
  
Learning Objectives: 
By reading this article you should be able to: 
• Classify acute pancreatitis and list its common causes 
• Explain the principles of investigation and supportive management of 
patients with acute pancreatitis 
• Describe the local complications of acute pancreatitis and understand 
the indications and options for intervention 
• Consider the potential long-term sequalae of patients following acute 
pancreatitis and strategies to prevent recurrence. 
 
  
Acute pancreatitis (AP) is an acute inflammatory disorder of the pancreas.  It 
is a leading cause of hospital admission for gastrointestinal disorders and the 
incidence is rising.1  Although the vast majority of these patients have a self-
limiting illness, severe acute pancreatitis has been shown to account for 2.4% 
of ICU bed occupancy in England & Wales with a corresponding hospital 
mortality of 40%.2  A previous article on Severe Acute Pancreatitis was 
published in Continuing Education in Anaesthesia, Critical Care & Pain a 
decade ago3. This article provides an update on classification and evidence-
based management of AP. 
 
Definitions and diagnostic criteria 
AP is diagnosed and classified according to the revised Atlanta criteria.4  
Diagnosis requires two or more of the following three criteria: 
 
1) Abdominal pain consistent with AP (severe, acute, persistent, 
epigastric pain, often radiating to the back) 
2) Serum amylase or lipase rise to greater than three times upper limit of 
normal 
3) Imaging evidence of AP (most commonly with contrast-enhanced CT) 
 
If there is clinical suspicion of acute pancreatitis without a significant serum 
enzyme rise (as may occur with delayed presentation) imaging may be 
required to confirm the diagnosis.  Conversely, even if the above two clinical 
/biochemical criteria are fulfilled, early CT imaging may be required to confirm 
the diagnosis. This will also help exclude other confounding pathology 
including perforated peptic ulcer or ischaemic bowel. 
 
Acute pancreatitis may be subdivided into two types: interstitial oedematous 
pancreatitis and necrotising pancreatitis.  The former accounts for more than 
80% of cases and typically manifests as mild disease in which pancreatic 
inflammation resolves without lasting local or systemic effects.  Necrotising 
pancreatitis manifests as necrosis of the pancreas and/or peripancreatic 
tissue and represents a more aggressive form of the disease with a far 
greater propensity for systemic complications.  
 
Defining Severity of AP: 
The revised Atlanta classification (2012) now defines three levels of severity: 
1) Mild AP: The absence of organ failure or local complications 
2) Moderate AP: Presence of ‘transient’ organ failure or local/systemic 
complications without persistent organ failure.  
3) Severe AP: Defined by the presence of persistent (>48 hours) organ 
failure  
 
More than a dozen pancreatitis-specific scoring systems have been 
developed in an attempt to identify early those at risk of complications. 
However, these are typically cumbersome and do not robustly predict 
outcome in a timeframe that is clinically useful. Instead it is recommended that 
patients with AP undergo; thorough clinical assessment, frequent monitoring 
(e.g. with Early Warning Scores) and regular review in order that organ 
dysfunction is recognised and addressed early.5  Predictive scoring systems 
may have a role in disease stratification in the context of clinical trials. 
 
Aetiology 
Gallstones and alcohol are the commonest causes of pancreatitis and 
account for more than two thirds of all cases.  Other causes are outlined in 
Table 1. 
 
The lifetime risk of AP in patients with incidentally detected gallstones is 
estimated to be less than 2%.6  However, when gallstones migrate into the 
biliary tree, they may cause transient obstruction of the pancreatic duct.  This 
provokes premature intracellular activation of digestive enzymes, 
‘autodigestion’ of pancreatic cells and an intense inflammatory response.  
This ‘obstructive’ mechanism may also occur at the time of contrast injection 
into the biliary tree during ERCP, accounting for the high incidence of AP 
following this procedure. 
 
Alcohol is thought to initiate AP via a direct toxic effect, though binge drinking 
does not appear to be a trigger.  Instead the risk seems related to sustained 
high alcohol intake.  The lifetime incidence of AP amongst chronic heavy 
drinkers in one German study was estimated to be less than 3%, indicating 
the importance of other factors such as genetics.7  Additional risk factors for 
developing AP include: type II diabetes, social deprivation, smoking and 
obesity.  Morbid obesity is associated with adverse outcomes in AP, including 
increased organ failure and mortality.  
  
Pathophysiology 
Two overlapping phases of AP are described.4 The early phase is 
characterized by systemic inflammation as a result of the host response to 
pancreatic injury.  Although the term ‘Systemic Inflammatory Response 
Syndrome (SIRS)’ is no longer utilised in the most recent sepsis definitions, it 
is a useful descriptor in this setting.  The spectrum of severity of systemic 
inflammation in AP may range from simple ‘SIRS’ with no organ dysfunction, 
to a precipitous decline with multi-organ failure and death.  The clinical picture 
may be indistinguishable from that of sepsis and mortality relates to the 
severity of organ failure and the number of systems involved.  Whilst local 
complications may be evident in the early phase of the disease, these do not 
tend to determine early adverse outcome.  For most patients, inflammation 
simply resolves, but a minority progress to develop a late phase, 
characterised by the evolution of local complications (with or without organ 
failure).   
 
Local complications include: necrosis and acute peripancreatic fluid 
collections (both of which may be either sterile or infected) as well as vascular 
complications and pancreatic fistula (see Table 2).  The most feared local 
complication is that of infected necrosis, but it is the presence or absence of 
accompanying organ failure that is the main determinant of mortality.  This 
observation has prompted calls for a four-tier classification to include the term 
‘critical pancreatitis’ in cases where infected necrosis is accompanied by 
organ failure.8  
 
 
Investigation: confirming the diagnosis, assessing aetiology and 
complications. 
Patients typically present with acute abdominal pain and routinely undergo 
blood tests including: FBC, U&E’s, LFT’s, glucose and serum amylase (or 
lipase).  Women of childbearing age should also have a pregnancy test as 
hyperamylasaemia may occur with ectopic pregnancy.  Further laboratory 
investigations such as coagulation screen, lactate, CRP, calcium and arterial 
blood gas analysis are used to assess the magnitude of inflammatory 
response and physiological compromise.  A chest X-ray will exclude 
significant pneumoperitoneum (though cannot exclude a perforated viscus) 
and may also demonstrate pleural effusions or pulmonary complications.  A 
12-lead ECG should also be performed to look for evidence of myocardial 
ischaemia.   
 
Early CT imaging should be performed where there is ‘diagnostic uncertainty’ 
and in all patients requiring ICU admission to robustly confirm the diagnosis 
and exclude other pathology. Intravenous contrast medium should be used, 
even in the setting of significant renal failure, in an effort to increase 
diagnostic yield.  On-going significant inflammatory response or organ 
dysfunction in the first week merits CT imaging to look for local complications.  
Patients with local complications and/or persistent organ failure will require 
regular imaging to monitor evolution of local complications and determine 
management. 
 
It is important to establish the aetiology, beginning with a thorough history 
including: alcohol consumption, medications, preceding symptoms of viral 
illness and family history of pancreatitis. All patients presenting with AP 
should undergo an ultrasound scan to look for gallstones and to assess for 
evidence of biliary dilatation. If negative, this should be repeated prior to 
discharge, as false negative results are not uncommon early in the disease.  
Hypercalcaemia as a potential causes of AP should be assessed on 
admission.  If negative this should also be repeated in the convalescent 
phase.  Conversely, hypertriglyceridaemia in the acute setting may occur as a 
consequence of the illness and should be repeated in the elective setting. 
Whilst some patients have “idiopathic pancreatitis” every effort should be 
made to determine aetiology as this offers potential for prevention of further 
attacks. In particular, patients with minimal alcohol consumption and / or 
recurrent episodes should undergo endoscopic ultrasound to evaluate the 
gallbladder and biliary tree for microlithiasis. 
 
 
Supportive Management of AP 
The majority of patients presenting with AP are assessed and managed on 
General Surgical wards.  Patients with evidence of organ dysfunction or at 
high risk of deterioration (e.g. elderly patients with chronic organ dysfunction 
or obese patients with evidence of significant systemic inflammatory 
response) are best managed in a critical care environment.   
 
Treatment of AP is entirely supportive.  As is the case with sepsis, numerous 
pharmacological strategies have been trialled to mitigate the inflammatory 
response or alter the outcome in AP but without any notable success.  The 
mainstays of initial management are fluid resuscitation and analgesia with 
supplemental oxygen if hypoxaemia is present.   
 
Fluid therapy: 
Patients frequently have significant intravascular depletion due to: decreased 
oral intake, vomiting, capillary leak and increased insensible losses 
(fever/tachpynoea).  In addition to ‘absolute hypovolaemia’, there may also be 
‘relative hypovolaemia’ due to vasodilatation.  Preclinical data suggest that 
pancreatic hypoperfusion occurs in AP and this may be attenuated by 
treatment with high-volume crystalloid resuscitation. Evidence from 
prospective clinical trials is limited and observational studies are difficult to 
interpret, given the likely confounding effect of disease severity on fluid 
prescribing behavior.9  
 
Guidelines from the American College of Gastroenterology recommend initial 
fluid resuscitation rates of 250-500ml/hour and suggest the benefit of fluid 
resuscitation is probably limited to the first 12-24 hours.5  It is likely that too 
much fluid is as harmful as too little, including increased risk of intra-
abdominal hypertension or abdominal compartments syndrome.10  However, 
quantifying optimal fluid resuscitation remains an elusive goal.  A large 
international study of fluid prescribing behaviour in ICU’s worldwide suggests 
that fluid-prescribing behaviour is highly variable and often irrational 11 and 
whilst a ‘one size fits all’ fluid resuscitation protocol is illogical, it is also difficult 
to define end points for individualized fluid resuscitation.  A systematic review 
of fluid administration in AP could not find any good quality evidence on which 
to base recommendations on fluid type, volume or rate of administration, nor 
could it make recommendations regarding specific resuscitation end points.9  
 
In the absence of specific good quality evidence it seems reasonable to 
extrapolate from practice in septic patients. Balanced crystalloid solution 
should be used to maintain organ perfusion targeting a urine output of 
>0.5ml/Kg/hr and ‘normalisation’ of serum lactate.  In the setting of systemic 
hypotension, the addition of vasopressors may be required and early addition 
of vasopressors may help to limit deleterious effects of high volume fluid 
resuscitation.   
 
Analgesia: 
AP is a painful condition and immediate and effective analgesia is the priority. 
Whilst this is given primarily on compassionate grounds it also impacts 
positively on patient physiology by reducing the stress response and 
minimising pulmonary complications such as atelectasis, lobar collapse and 
lower respiratory tract infection.  There is no good quality evidence to guide 
analgesic strategy in AP and clinical practice generally follows the standard 
analgesic ladder.12  An international multicenter RCT, which aims to 
investigate the role of epidural anaesthesia in patients with AP admitted to 
ICU is currently ongoing.13   
 
Non-steroidal analgesics should be avoided and parenteral opiates and 
paracetamol used instead until reliable gut absorption is demonstrated. 
Multimodal anti-emetics are given as required. A minority of patients may 
require patient controlled analgesia in order to effectively manage their pain. 
 
Antibiotics: 
Pancreatitis is a sterile inflammatory process. Although bacterial infection may 
co-exist with AP (e.g. concomitant cholangitis or pneumonia) or develop in 
previously sterile sites (e.g. infected pancreatic necrosis), the routine use of 
antibiotics is not recommended.5, 14 Instead, antibiotics should be reserved for 
those with proven or suspected bacterial infection, ideally based on cultured 
organisms. In particular, positive drain cultures should not be treated with 
antibiotics unless there is concern regarding adequacy of source control.  Fine 
needle aspiration of collections for culture was previously advocated but 
concerns regarding inoculation of sterile collections have led to this technique 
falling out of favour. 
 
Prevention of pulmonary complications: 
Early effective analgesia aims to prevent complications associated with 
‘diaphragmatic splinting’ and hypoventilation. 
 
There is an association between large volume fluid resuscitation and 
pulmonary complications and AP is a potent stimulus for development of 
ARDS.  After the initial resuscitation period (in which the aim is to restore 
circulating volume) fluid administration should be minimised.  Supplemental 
oxygen aims to maintain oxygen saturations greater than 94% and 
increasingly, high flow nasal oxygen has been used to avoid mechanical 
ventilation.   
 
Prevention of renal complications: 
Nephrotoxic drugs should be stopped on admission to hospital. Intravascular 
volume and an adequate perfusing pressure should be restored as part of the 
initial resuscitation as outlined above.  Balanced crystalloid resuscitation may 
avoid adverse renal outcomes associated with starch solutions and chloride-
rich resuscitation fluids.  
 
Glycaemic control: 
Hyperglycaemia commonly accompanies AP.  This is likely due to a 
combination of stress-mediated ‘counter regulatory’ hormones and loss of 
functioning pancreatic islet cells.  There is no evidence to support ‘intensive’ 
glucose control over ‘conventional’ glucose control (<10mMol/l) in AP and the 
former may be harmful.15 This is compatible with the findings of a large, 
multinational, randomized controlled study in a mixed ICU population.16 
 
Nutrition: 
Patients with mild AP can eat and drink as soon as they desire.  There is no 
evidence to support ‘resting’ the pancreas, nor is there evidence to support 
early enteral nutritional support.17   
 
Nutritional support is recommended if normal diet cannot be established 
within 5-7 days.18  In these circumstances, enteral nutrition appears to lead to 
fewer complications than parenteral nutrition.  Enteral feed should be 
delivered via the NG route.  The NJ route is only required when NG feeding is 
not tolerated (e.g. gastric outlet obstruction due to local complications) or, 
occasionally, when feeding distal to a foregut fistula is required.   
 
Traditionally, elemental and semi-elemental feeds have been used based on 
the assumption that these cause less pancreatic stimulation than standard 
polymeric feeds but there is inadequate evidence to support this practice.19  
Similarly, probiotics and specific immunonutrition supplementation cannot 
currently be recommended. 
 
Total Parenteral Nutrition is used rarely and is largely reserved for those 
patients with either a non-functioning gut or those with complex enteric 
fistulae. 
 
Management of gallstones 
It is imperative that gallstones, when present, are identified and definitively 
managed in a bid to prevent recurrent pancreatitis.  Timing of 
cholecystectomy is dependent on the severity of pancreatitis.  In mild disease 
it is recommended that cholecystectomy be performed prior to discharge, 
though this often poses logistical challenges.  In severe pancreatitis, months 
of convalescence may be required before surgery is considered.  
Choledocholithiasis (stones in the bile duct) may be identified on pre-
operative imaging (e.g. MRCP) or via cholangiography at the time of surgery.  
Strategies for managing bile duct stones include ERCP and operative bile 
duct exploration at the time of cholecystectomy.  ERCP and endoscopic biliary 
sphincterotomy may also be utilised as ‘definitive management’ in a bid to 
prevent recurrent attacks in those deemed unfit to undergo cholecystectomy.  
ERCP has no role in the early management of acute pancreatitis, unless there 
is co-existing cholangitis (when it is required urgently to allow decompression 
of the biliary system for ‘source control’). This may be a difficult judgement call 
as deranged LFT, an elevated serum amylase and an inflammatory response 
may occur in both acute pancreatitis and cholangitis. Every effort should be 
made to avoid unnecessary ERCP in the context of AP as the risks are high, 
including inoculation of previously sterile necrosis or collections. A pragmatic 
strategy of serial LFT for the first 24-48 hours helps differentiate these 
conditions: a transient rise in bilirubin suggests a passed stone in a patient 
with AP, whilst a persistent or rising bilirubin is more likely consistent with 
biliary obstruction and cholangitis. 
 
 
Indications for Tertiary Referral: 
It is recommended that patients with severe pancreatitis or those with a 
hospital stay of more than two weeks after the onset of symptoms should be 
managed by, or in consultation with, a specialist pancreatic team.20  Local 
referral pathways should be agreed. Early discussion with the specialist unit is 
advised and many patients are now co-managed “remotely” with the 
assistance of electronic radiology systems. 
 
 
Endoscopic, radiological and surgical management of local 
complications 
 
“First, do nothing”: 
The majority of local complications do not require any intervention and the 
prevailing ethos should be to conservatively manage local complications 
unless forced to act by: uncontrolled sepsis, bleeding or failure to progress.   
 
Necrosis: 
There is no role for prophylactic antibiotics and sterile necrosis rarely requires 
intervention (except in rare circumstances when it causes obstruction of the 
GI tract or biliary tree).  The main indication for intervention is the 
development of infected necrosis.  It is widely accepted that intervention in the 
first two weeks of severe acute pancreatitis should be avoided if at all possible 
because of the high associated mortality.  In rare cases, such as major intra-
abdominal haemorrhage or secondary bowel ischaemia requiring laparotomy 
in the first weeks, it is best to avoid disturbing the pancreatic inflammatory 
mass if possible.20  
 
If required, pancreatic intervention should be delayed until ‘walled-off 
necrosis’ has developed, typically 3-5 weeks after the onset of symptoms.  
This allows demarcation of the boundary between healthy and necrotic tissue, 
liquefaction of the contents, and formation of a defined wall around the 
collection.21  Indications for intervention include: confirmed or suspected 
infection of necrotic tissue and persistent organ failure with a walled-off 
collection.20  If infected necrosis is suspected then antibiotics should be 
initiated.  Antibiotics may permit drainage or debridement to be safely delayed 
until maturation of walled off necrosis and antibiotics alone may suffice in 
some patients.22  There is randomized controlled trial evidence to support a 
“step-up” approach of antibiotics with percutaneous drainage, followed by 
minimally invasive surgical necrosectomy, if required. This approach reduced 
major morbidity by 43% when compared to open necrosectomy, and more 
than one third of patients in the ‘step up’ group required only percutaneous 
drainage.23  Minimally invasive necrosectomy is performed by ‘upsizing’ the 
percutaneous drain under general anaesthesia. This tract is then used to 
access and debride the necrotic collection with a rigid endoscope. 
Consideration should therefore be given to the siting of the initial drain and a 
left flank approach is often preferred. Endoscopic necrosectomy is gaining 
traction and involves accessing the collection from the foregut (usually 
stomach) under EUS guidance. A recent Dutch randomised trial comparing 
endoscopic versus surgical step-up approach suggested equivalence in terms 
of a composite end-point of mortality or major complications but shorter 
hospital stay and reduced pancreatic fistulae with endoscopic therapy.23 
Regardless of the approach, the key principle is the same: control of sepsis by 
relieving “pus under pressure”. Debridement of necrotic tissue per se is not 
required for sepsis resolution but rather to facilitate drainage of pus. 
 
Pancreatic Pseudocyst: 
This is an encapsulated collection of fluid with a well-defined inflammatory 
wall, usually outside the pancreas, with minimal or no necrosis.4  They are 
therefore very rare after acute pancreatitis as necrosis to some extent is 
invariably present.  These usually evolve more than four weeks after onset of 
pancreatitis and contain sterile, enzyme-rich fluid.  Secondary infection can 
occur.  Most resolve spontaneously without any intervention.  The main 
indications for intervention are: persistent pain, infection of the pseudocyst, 
bleeding and obstructive symptoms (e.g. gastric outlet obstruction).  
Pseudocysts may be drained percutaneously, endoscopically or surgically 
(e.g. drainage into the stomach via open or laparoscopic approach).  A recent 
systematic review comparing these strategies found inadequate evidence to 
strongly support practice but concluded that endoscopic ultrasound guided 
drainage appeared to be advantageous in drainage of pancreatic pseudocysts 
located adjacent to the stomach or duodenum.24  A tailored therapeutic 
approach involving a specialist multidisciplinary team including: radiologist, 
therapeutic endoscopist and pancreatic surgeon is recommended.  
 
Splenic / Mesenteric / portal venous thrombosis: 
Intense inflammation adjacent to major venous structures may lead to 
splanchnic venous thrombosis, most commonly affecting the splenic, portal or 
superior mesenteric veins.  Splenic vein thrombosis has has been reported in 
23% of patients with acute pancreatitis undergoing imaging.  Approximately 
half of these patients go on to develop splenomegaly and gastro-oesophageal 
varices due to ‘segmental portal hypertension’ and an associated GI bleeding 
rate of 12% is reported.25 Spontaneous recanalisation occurs in approximately 
one third of cases.  Risks and benefits of anticoagulation in should be 
assessed on a case-by-case basis. In general, thrombus involving the 
superior mesenteric vein or portal vein is managed with anticoagulation for 3-
6 months in the absence of a contra indication. Splenic vein thrombosis is 
usually managed without anticoagulation.  
 
Arterial Pseudoaneurysm: 
Major vascular complications occur with a frequency of up to 6% in acute 
pancreatitis and the mortality associated with this is reported to be greater 
than 30%.26 Asymptomatic arterial pseudoaneurysm of splenic or hepatic 
arterial branches may be identified on CT imaging.  These are associated with 
a high risk of bleeding and prophylactic transcatheter arterial embolisation is 
recommended. Embolisation is also the first-line treatment in the event of 
acute haemorrhage. CT angiography may provide a “roadmap” in the bleeding 
patient. This is determined by patient physiology and the unstable patient 
should bypass CT and be transferred directly to the interventional radiology 
(IR) theatre for resuscitation concurrent with haemorrhage control. 
 
In the event that IR fails a surgical approach is often necessary. This is one of 
the most technically challenging operative procedures in pancreatic surgery. 
Access to the culprit vessel is compromised by the inflammatory process and 
the most rapid approach to the retroperitoneum is often best-achieved 
transgastrically. 
 
  
Sequalae of Acute Pancreatitis and preventing recurrence 
The majority of patients have mild disease and pancreatic inflammation 
resolves without long-term effects.  Furthermore, the majority of those with 
local complications (e.g. acute fluid collections) resolve spontaneously without 
intervention.  Transition from acute pancreatitis to chronic pancreatitis 
predominantly occurs in alcohol-induced AP and smoking is a risk factor for 
this. 
 
Patients with significant necrosis should be assumed to have exocrine 
insufficiency and empirically treated with enzyme supplements.  There may be 
some functional recovery over the ensuing months and exocrine function can 
be reassessed by means of faecal elastase testing or on clinical grounds.  
Endocrine insufficiency should also be considered and monitored in these 
patients.  Survivors of severe acute pancreatitis may have long-term 
impairment of organ function.  Patients admitted to ICU with AP have a length 
of stay twice that of the average critical care patient.2  Consequently they are 
particularly prone to the sequalae of ‘post-ICU syndrome’, including cognitive, 
psychiatric and physical disabilities. 
 
Prevention of recurrence requires a thorough search for causative factors, 
most notably a thorough search to exclude and manage gallstones.  Those 
with alcohol-induced AP should receive structured support to promote 
abstinence.  Other modifiable causes (hypertriglyceridaemia, hypercalcaemia, 
medications, auto-immune disease) should also be addressed. 
 
  
Summary 
The incidence of AP is increasing.  For the vast majority of patients, it is a 
self-limiting disease requiring ward-based supportive care and a thorough 
assessment of aetiology in a bid to prevent recurrence.  Those with 
moderate/severe disease, however, may require extensive critical care 
resources and specialist radiological, endoscopic and surgical input.  This is 
best provided in conjunction with regional specialist units. 
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Legends to Tables and Figures: 
 
Table 1: Causes of acute pancreatitis.  
 
Table 2: Local complications of acute pancreatitis 
  
Table 1 
‘Obstructive’ mechanism Gallstones  
ERCP 
Neoplasm (rare) 
Pancreas Divisum (controversial) 
Sphincter of Oddi (controversial) 
Cystic Fibrosis 
‘Toxic’ mechanism Chronic Alcohol Excess 
Hypertriglyceridaemia 
Drugs: Steroids, Azathioprine, 
Oestrogens, Furosemide, Thiazides, 
Sulphonamides, Metronidazole 
Hypercalcaemia 
Hyperparathyroidism 
Scorpion / Snake bites (rare) 
Genetic causes (rare) Alpha-1-Antitrypsin deficiency 
Autoimmune (rare) Sclerosing cholangitis 
Trauma Blunt or Penetrating 
Infection Viruses: CMV, mumps, coxsackie B, 
EBV 
Parasites: Ascaris & clonorchis 
Ischaemia/ reperfusion Cardio-pulmonary bypass 
Shock states 
Vasculitides 
Hypothermia  
Idiopathic  
Other associated risk 
factors 
Diabetes, Obesity, Smoking 
Table 2 
 
Local inflammation Pancreatic / peripancreatic collections 
• Acute Peripancreatic Fluid Collection  
• Acute Necrotic Collection 
• Walled of Necrosis 
• Pancreatic Pseudocyst 
 
Pancreatic abscess 
Pancreatic Fistulae 
Vascular 
complications 
Splanchnic Venous Thromboses 
• Splenic vein  
• Superior mesenteric vein  
• Portal vein thrombosis 
 
Arterial 
• Pseudoaneurysm (splenic, gastroduodenal, 
aorta) 
• Bleeding  
 
Other regional Abdominal Compartment Syndrome 
Paralytic ileus 
Systemic Systemic venous thrombosis 
Acute respiratory distress syndrome 
Acute Kidney Injury 
 
  
MCQ’s: 
 
A 35-year-old man with a history of type II diabetes and morbid obesity (Body Mass 
Index 37 Kg/m2) presented to hospital with severe upper abdominal pain and 
vomiting and was found to have a serum amylase that was seven times the upper 
limit of normal.  He had just returned from a ‘stag weekend’ during which he had 
consumed more than 20 units/day of alcohol, though he does not habitually drink 
alcohol.  Chest X-ray showed no abnormalities.  
 
a) A CT scan of the abdomen is mandatory to confirm the diagnosis of acute 
pancreatitis 
b) The most likely aetiology of acute pancreatitis in this case is alcohol 
c) Diabetes is a risk factor for acute pancreatitis 
d) Obesity is a risk factor for developing severe acute pancreatitis 
e) Serum calcium should be checked on admission to exclude hypercalcaemia as 
the cause of acute pancreatitis 
 
  
Answers: 
a) False.  CT imaging is only required when there is diagnostic uncertainty.  It is 
not mandatory and acute pancreatitis is most commonly diagnosed on the 
basis of typical clinical features and serum enzyme (amylase or lipase) rise. 
b) False.  Gallstones are the commonest cause of acute pancreatitis and ‘binge 
drinking’ (cf. chronic heavy alcohol use) does not appear to confer risk.   
c) True 
d) True.  Morbid obesity is associated with adverse outcomes in acute 
pancreatitis, including increased organ failure and increased mortality. 
e) False.  A serum calcium level may be informative if high, however, calcium 
may be ‘sequestered’ in necrotic tissue during an episode of acute 
pancreatitis and may, therefore, give a false negative result in the acute 
phase.  Hypercalcaemia as an aetiology cannot be excluded acutely and the 
serum calcium level should be re-checked in the convalescent stage. 
 
 
  
Abdominal ultrasound scan has demonstrated multiple gallstones in the gallbladder 
and dilation of the common bile duct (8mm).  He was initially jaundiced but this has 
now resolved.  Blood test confirm that his bilirubin has fallen to 28 micromoles/litre.  
He is exhibiting an ongoing ‘Systemic Inflammatory Response Syndrome’ six days 
after the onset of pain though there is no evidence of organ dysfunction. Contrast CT 
revealed decreased enhancement of the body of the pancreas consistent with 
pancreatic necrosis.  He is not on antibiotics. 
 
a) This patient has severe acute pancreatitis 
b) An urgent ERCP is indicated to decompress the biliary tree 
c) Antibiotics are not currently indicated 
d) Enteral Nutrition is preferred over Parenteral Nutrition. 
e) He should undergo a Cholecystectomy within 7 days to prevent further 
episodes of acute pancreatitis 
 
  
Answers: 
a) False: He has local complications (necrosis) but does not currently have organ 
failure.  By the revised Atlanta classification this would be considered 
‘moderate’ rather than severe disease currently. 
b) False: The normalising bilirubin suggests he does not have cholangitis and 
therefore urgent ERCP is not required.  He currently has no organ 
dysfunction.  ERCP in this setting would confer a risk of introducing infection 
into what is most likely sterile pancreatic necrosis. 
c) True. This is most likely a sterile process currently.  Guidelines advocate 
avoiding prophylactic antibiotics, even in the setting of necrosis, and instead 
reserving antibiotics for proven or highly suspected infection. 
d) True. Parenteral nutrition is really only indicated when the enteral route is 
unavailable. 
e) False.  In the setting of pancreatic necrosis or persistent organ dysfunction, 
definitive management of gallstones should be delayed.  In patients with mild 
acute gallstone pancreatitis cholecystectomy would ideally be performed 
without delay to reduce the risk of recurrence. 
 
 
  
10 days later he is receiving ventilatory support for severe respiratory failure (PaO2: 
FiO2  = 12 KPa).  Repeat CT imaging reveals widespread pancreatic necrosis containing 
gas locules.  In addition, radiological features consistent with Acute Respiratory 
Distress Syndrome (ARDS) are evident. 
 
a) Aggressive fluid resuscitation is required to improve pancreatic perfusion 
b) CT imaging in this clinical setting should be performed with intravenous 
contrast. 
c) Enteral feeding should preferentially be administered via a naso-jejunal tube 
d) Prone ventilation should be considered 
e) Urgent transfer to a regional pancreatic surgery unit is required for definitive 
management 
 
  
Answers: 
 
a) False.  It is thought that fluid resuscitation in the first 12-24 hours may 
mitigate pancreatic hypoperfusion but this would not be likely to help at this 
stage of the illness.  Furthermore, in the setting of ARDS, aggressive fluid 
resuscitation may be detrimental. 
b) True.  Contrast is required to adequately assess local complications, including 
vascular complications.  The risk of contrast nephropathy is accepted in this 
setting. 
c) False.  Most patients can be fed via the naso-gastric route.  Naso-jejunal 
feeding may be required if this fails. 
d) True.  Whilst there may be valid concerns regarding the effects of prone 
positioning on intra-abdominal hypertension in this setting, severe acute 
pancreatitis is not an absolute contra-indication to prone ventilation and it 
should be considered given his severely impaired oxygenation.  
e) False.  Whilst there is radiological evidence of infected necrosis it is too early 
to intervene.  In the early phase, infected necrosis is best managed with 
antimicrobials and supportive care.  Liaison with the regional pancreatic unit 
is recommended but currently the risks of transfer would not be justified. 
 
  
2 months later his organ failure has resolved and he is recovering in the High 
Dependency Unit.  He has undergone several minimally invasive necrosectomy 
procedures over the last 5 weeks.  Splenic vein thrombosis was noted on recent 
imaging.  He has a residual large drain in the left flank.  He suddenly deteriorates 
with a large volume haematemesis and clinical evidence of shock.  There is no 
evidence of blood in the drain. 
 
a) An emergency upper GI endoscopy is required to achieve haemorrhage 
control 
b) Gastric varices (secondary to segmental portal hypertension) as a result of 
splenic vein thrombosis is the most likely site of bleeding 
c) He was likely to have been systemically anticoagulated given that splenic vein 
thrombosis had been diagnosed. 
d) Vascular complication are rare in patients with severe acute pancreatitis 
(<1%) 
e) The mortality associated with major bleeding complications exceeds 10%. 
 
  
Answers: 
 
a) False.  Upper GI endoscopy is the usual first-line step for haemorrhage 
control in patients with haematemesis.  However, in this setting, the most 
likely source of bleeding is rupture of a pseudo-aneurysm of one of the 
coeliac artery branches (e.g gastroduodenal or splenic artery branches).  
Mesenteric angiography will be required to control bleeding and should be 
considered first-line. 
b) False.  Gastric varices are a long-term complication of splenic vein thrombosis 
and do not typically cause early bleeding.  Arterial complications are more 
likely. 
c) False.  Splenic vein thrombosis alone is not usually considered to be an 
indication for anticoagulation.  Thrombosis affecting the superior mesenteric 
or portal vein may be considered to require anticoagulation. 
d) False.  Major arterial complications are reported to occur in 6% of patients 
and splanchnic vein thromboses may be detected in up to a quarter of all 
patients undergoing CT imaging. 
e) True.  The associated mortality is reported to be greater than 30%. 
 
